In addition, we demonstrated that FGF-R expression in prostate cancer cells did not augment whether co-cultured with HUVEC or following docetaxel treatment, which suggested that the increasing FGF2 derived from HUVEC cells was the primary factor that contributed to the FGF2/FGFR signaling pathway. This evidence concerns the gene FGF2 and prostate carcinoma.